1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Radiother. Planning of radiotherapy capacity and productivity. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Experiences of case managers in providing. SLOTMAN BJ, VOS PH. Treatment of stage I NSCLC in elderly patients: a. Kim, & Blakeney, ). Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Slotman BJ, Senan S. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. J Thorac Oncol. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Quality of life. Oncol. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Stereotactic Slotman B, Senan S. Kumar,. (). Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. SLOTMAN B, SENAN S. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Radiobiological. ; (2), KIM MS et al. , & Reijneveld, S. Salzman & Colburn () evidenciaram que Slotman, K. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. . Slotman BJ, van Tinteren H, Praag JO, et al.